000			01983 a2200589 4500
005			20250518085320.0
264		0	_c20201112
008			202011s 0 0 eng d
022			_a2045-2322
024	7		_a10.1038/s41598-020-58366-z _2doi
040			_aNLM _beng _cNLM
100	1		_aWang, Yudong
245	0	0	_aPhase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. _h[electronic resource]
260			_bScientific reports _c02 2020
300			_a3080 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAngiogenesis Inhibitors _xadverse effects
650	0	4	_aBoron Compounds _xadverse effects
650	0	4	_aGlycine _xadverse effects
650	0	4	_aHumans
650	0	4	_aIndazoles
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMiddle Aged
650	0	4	_aMutation _xgenetics
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aProgression-Free Survival
650	0	4	_aPyrimidines _xadverse effects
650	0	4	_aSulfonamides _xadverse effects
650	0	4	_aTreatment Outcome
650	0	4	_aTumor Suppressor Protein p53 _xgenetics
650	0	4	_aVorinostat _xadverse effects
650	0	4	_aYoung Adult
700	1		_aJanku, Filip
700	1		_aPiha-Paul, Sarina
700	1		_aHess, Kenneth
700	1		_aBroaddus, Russell
700	1		_aLiu, Lidong
700	1		_aShi, Naiyi
700	1		_aOverman, Michael
700	1		_aKopetz, Scott
700	1		_aSubbiah, Vivek
700	1		_aNaing, Aung
700	1		_aHong, David
700	1		_aTsimberidou, Apostolia M
700	1		_aKarp, Daniel
700	1		_aYao, James
700	1		_aFu, Siqing
773	0		_tScientific reports _gvol. 10 _gno. 1 _gp. 3080
856	4	0	_uhttps://doi.org/10.1038/s41598-020-58366-z _zAvailable from publisher's website
999			_c30656247 _d30656247